NF-κB: a therapeutic target in inflammatory diseases

2001 ◽  
Vol 5 (2) ◽  
pp. 197-204 ◽  
Author(s):  
Christine L Curran ◽  
Timothy S Blackwell ◽  
John W Christman
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases

Discovery of new polycyclic polyprenylated acylphloroglucinols with diverse architectures as potent cyclooxygenase-2 inhibitors

2020 ◽  
Vol 7 (11) ◽  
pp. 1349-1357 ◽  
Author(s):  
Shuangshuang Xie ◽  
Changxing Qi ◽  
Yulin Duan ◽  
Qianqian Xu ◽  
Yaping Liu ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases ◽  
Cyclooxygenase 2 ◽  
Chronic Inflammatory Diseases ◽  
Cox 2 ◽  
Cyclooxygenase 2 Inhibitors

Cyclooxygenase-2 (COX-2) is a significant therapeutic target of chronic inflammatory diseases.

scholarly journals IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis

2008 ◽  
Vol 181 (1) ◽  
pp. 669-679 ◽  
Author(s):  
Lone Skov ◽  
Frank J. Beurskens ◽  
Claus O. C. Zachariae ◽  
Sakari Reitamo ◽  
Jessica Teeling ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases ◽  
Clinical Activity ◽  
Palmoplantar Pustulosis

The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic?

2021 ◽  
pp. 239719832110394
Author(s):  
Silvia Bellando-Randone ◽  
Emanuel Della-Torre ◽  
Andra Balanescu
Keyword(s):  
Systemic Sclerosis ◽  
Therapeutic Target ◽  
Inflammatory Diseases ◽  
Adaptive Immune System ◽  
Disease Stage ◽  
Target Cells ◽  
Interleukin 17 ◽  
T Helper 17 ◽  
Attractive Therapeutic Target

Systemic sclerosis is characterized by widespread fibrosis of the skin and internal organs, vascular impairment, and dysregulation of innate and adaptive immune system. Growing evidence indicates that T-cell proliferation and cytokine secretion play a major role in the initiation of systemic sclerosis, but the role of T helper 17 cells and of interleukin-17 cytokines in the development and progression of the disease remains controversial. In particular, an equally distributed body of literature supports both pro-fibrotic and anti-fibrotic effects of interleukin-17, suggesting a complex and nuanced role of this cytokine in systemic sclerosis pathogenesis that may vary depending on disease stage, target cells in affected organs, and inflammatory milieu. Although interleukin-17 already represents an established therapeutic target for several immune-mediated inflammatory diseases, more robust experimental evidence is required to clarify whether it may become an attractive therapeutic target for systemic sclerosis as well.

Calcium influx, a new potential therapeutic target in the control of neutrophil-dependent inflammatory diseases in bovines

2011 ◽  
Vol 143 (1-2) ◽  
pp. 1-10 ◽  
Author(s):  
R.A. Burgos ◽  
I. Conejeros ◽  
M.A. Hidalgo ◽  
D. Werling ◽  
C. Hermosilla
Keyword(s):  
Therapeutic Target ◽  
Calcium Influx ◽  
Inflammatory Diseases ◽  
Potential Therapeutic Target

MicroRNA-155 as a therapeutic target for inflammatory diseases

2012 ◽  
Vol 33 (3) ◽  
pp. 557-560 ◽  
Author(s):  
Naghmana Kanwal ◽  
Peter John ◽  
Attya Bhatti
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases

Extracellular HMGB1 as a therapeutic target in inflammatory diseases

2018 ◽  
Vol 22 (3) ◽  
pp. 263-277 ◽  
Author(s):  
Ulf Andersson ◽  
Huan Yang ◽  
Helena Harris
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases

scholarly journals KCNN4 Expression Is Elevated in Inflammatory Bowel Disease: This Might Be a Novel Marker and Therapeutic Option Targeting Potassium Channels

2020 ◽  
Vol 29 (4) ◽  
pp. 539-547
Author(s):  
Christoph Süss ◽  
Lucile Broncy ◽  
Kirstin Pollinger ◽  
Claudia Kunst ◽  
Karsten Gülow ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases ◽  
Therapeutic Option ◽  
Cell Monolayer ◽  
Secretory Diarrhea ◽  
K Channel ◽  
Epithelial Barrier ◽  
Mrna Levels ◽  
Inflammatory Bowel

Background and Aims: The K + channel KCNN4 is involved in many inflammatory diseases. Previous work has shown that this channel is involved in epithelial ion transport and intestinal restitution. In inflammatory bowel diseases (IBD) a defective epithelial barrier can lead to typical symptoms like secretory diarrhea and the formation of intestinal ulcers. We compared surgical samples from patients with IBD, diverticulitis and controls without inflammation to determine the potential role of KCNN4 as a diagnostic marker and/or therapeutic target. Methods: mRNA-levels of KCNN4 and a control K + channel were determined in intestinal epithelial cells (IEC) from patients with IBD, diverticulitis and controls. In addition, we performed a Western blot analysis of KCNN4 and a respective control K + channel in IEC from patients with IBD. Furthermore, we determined epithelial barrier integrity by measuring the flux of fluorescent-labeled dextran beads across a cell monolayer upon incubation with interferon-γ. Results: KCNN4 mRNA and protein levels were elevated in IEC from patients with Crohn`s disease (CD) and ulcerative colitis (UC). Of note, KCNN4 was not elevated in non-IBD intestinal inflammatory conditions e.g. diverticulitis. Of clinical relevance, pharmacological KCNN4 channel openers stabilized epithelial barrier function in vitro. Thus, KCNN4 may have a protective role in IBD and constitute a therapeutic target. Conclusions: Our data demonstrate elevated KCNN4 both at mRNA and protein level in IEC specifically from patients with IBD. Therefore, we conclude that KCNN4 could be used as a novel marker for IBD, especially for the establishment of initial diagnosis. Of therapeutic consequence, we show that pharmacological KCNN4 openers stabilize the epithelial barrier. Thus, KCNN4 might be a novel target to diagnose and treat IBD.

scholarly journals Modulation of the CCR6-CCL20 Axis: A Potential Therapeutic Target in Inflammation and Cancer

2018 ◽  
Author(s):  
Ranmali Ranasinghe ◽  
Rajaraman Eri
Keyword(s):  
Therapeutic Target ◽  
Inflammatory Diseases ◽  
Polyclonal Antibodies ◽  
Research Field ◽  
Peptide Inhibitors ◽  
Disease Symptoms ◽  
Autoimmune And Inflammatory Diseases ◽  
Clinical Models ◽  
Antibody Preparations ◽  
Cell Chemotaxis

Prototypical functions of the chemokine receptor CCR6 include immune regulation by manoeuvring cell chemotaxis and selective delimiting of the pro-inflammatory TH17 and regulatory Treg subsets during chronic or acute systemic inflammation. Inhibition of CCR6 is proposed to attenuate disease symptoms and promote recuperation of multiple inflammatory and autoimmune disorders. Prescription medicines with pharmacodynamics involving the inhibition of the chemokine axis CCR6-CCL20 is very limited. Developing such therapeutics is still at an early experimental stage which has mostly utilized pre-clinical models and neutralizing mono or polyclonal antibodies against either partner, CCR6 or CCL20. Other methods have been constitutive use of small molecules as peptide inhibitors or small interfering ribonucleic acid (siRNA) to interfere with transcription at the nuclear level. We in our review aim at introducing the wide array of potential CCR6-CCL20 inhibitors that have been tried to date in the research field with accent on attendant immune-modulator capacity and which are immensely promising compounds as forerunners of future curatives. 16 different tractable inhibitors of the CCR6-CCL20 duo have been identified to possess high medicinal potential to the drug developers worldwide to treat autoimmune and inflammatory diseases. A multitude of antibody preparations are already available in the current pharmaceutical market as patented treatment for diseases in which the CCR6-CCL20 axis is operative, yet must be used only as supplements with existing routinely prescribed medication as they collectively produce adverse side effects. Novel inhibitors are needed to evaluate this invaluable therapeutic target which holds much promise in the research and development of complaisant remedies for inflammatory diseases.

Sign in / Sign up

Export Citation Format

Share Document